EdgeMarket › What Vr Adviser, Llc reported owning
What Vr Adviser, Llc reported owning
As filed on Form 13F for the quarter ending 2026-03-31, up to 45 days after that date. Long-only US-listed equity — shorts, bonds, cash and non-US listings are not on the form, so this is one leg of the book, not the book.
Reported value
2.7BPositions
33Quarter
2026-03-31Shown below
33largest by value
| holding | value | % of book | shares | price | 1y |
|---|---|---|---|---|---|
| APGE Apogee Therapeutics, Inc. | 714.9M | 26.7% | 8.5M | 134.75 | +274.1% |
| ERAS Erasca, Inc. | 265.1M | 9.9% | 16.4M | 17.63 | +1107.5% |
| ORKA Oruka Therapeutics, Inc. | 203.5M | 7.6% | 4.1M | 107.96 | +649.7% |
| SYRE Spyre Therapeutics, Inc. | 185.9M | 6.9% | 3.7M | 106.49 | +551.3% |
| unmapped CUSIP 483497103 | 130.3M | 4.9% | 6.5M | — | — |
| DNTH Dianthus Therapeutics, Inc. /DE/ | 99.0M | 3.7% | 1.2M | 111.10 | +374.4% |
| DMRA Damora Therapeutics, Inc. | 93.3M | 3.5% | 3.6M | 30.82 | +811.9% |
| OCUL OCULAR THERAPEUTIX, INC | 87.6M | 3.3% | 10.3M | 11.08 | -7.4% |
| COGT Cogent Biosciences, Inc. | 77.0M | 2.9% | 2.0M | 36.73 | +209.6% |
| VRDN Viridian Therapeutics, Inc.\DE | 75.9M | 2.8% | 3.9M | 24.29 | +33.9% |
| SVRA Savara Inc | 75.0M | 2.8% | 13.7M | 5.59 | +80.9% |
| ELVN Enliven Therapeutics, Inc. | 67.7M | 2.5% | 1.7M | 59.82 | +204.3% |
| ORIC Oric Pharmaceuticals, Inc. | 54.7M | 2.0% | 4.3M | 14.20 | +49.3% |
| VOR Vor Biopharma Inc. | 54.3M | 2.0% | 3.0M | 23.36 | -46.9% |
| MAZE Maze Therapeutics, Inc. | 47.8M | 1.8% | 1.6M | 29.43 | +118.3% |
| CTMX CytomX Therapeutics, Inc. | 46.9M | 1.8% | 10.0M | 3.28 | +66.5% |
| JBIO Jade Biosciences, Inc. | 45.2M | 1.7% | 3.2M | 21.34 | +211.5% |
| DYN Dyne Therapeutics, Inc. | 39.4M | 1.5% | 2.2M | 26.10 | +118.0% |
| CBIO CRESCENT BIOPHARMA, INC. | 39.2M | 1.5% | 2.1M | 17.15 | +24.3% |
| ZURA Zura Bio Ltd | 38.3M | 1.4% | 6.4M | 5.85 | +234.3% |
| RLMD RELMADA THERAPEUTICS, INC. | 33.7M | 1.3% | 4.8M | 4.63 | +655.9% |
| ENGN enGene Therapeutics Inc. | 32.5M | 1.2% | 4.8M | 1.78 | -53.9% |
| TENX TENAX THERAPEUTICS, INC. | 26.8M | 1.0% | 1.7M | 1.75 | -70.7% |
| ANL Adlai Nortye Ltd. | 22.2M | 0.8% | 3.2M | 13.70 | +720.4% |
| IPSC Century Therapeutics, Inc. | 19.7M | 0.7% | 8.7M | 2.07 | +279.8% |
| CGEM Cullinan Therapeutics, Inc. | 19.6M | 0.7% | 1.4M | 21.68 | +190.2% |
| HELP CYBIN INC. | 18.5M | 0.7% | 3.9M | 12.59 | +90.8% |
| SRZN Surrozen, Inc./DE | 18.4M | 0.7% | 632.9K | 23.99 | +108.6% |
| SEPN Septerna, Inc. | 12.2M | 0.5% | 506.1K | 40.00 | +260.7% |
| KRRO Korro Bio, Inc. | 11.4M | 0.4% | 1.0M | 13.18 | -31.6% |
| ANRO Alto Neuroscience, Inc. | 11.2M | 0.4% | 500.0K | 34.28 | +899.4% |
| ARTV Artiva Biotherapeutics, Inc. | 10.4M | 0.4% | 1.6M | 10.93 | +303.3% |
| XFOR X4 Pharmaceuticals, Inc | 1.4M | 0.1% | 330.5K | 4.04 | +44.3% |
A position that grew quarter on quarter may simply reflect a higher price: if the stock rose 40% and the manager did nothing, the reported value rose 40%. Reading that as accumulation is reading the price back to yourself. More on that →
The whole archive is one click away.
Screener, filings, insider flow, backtests and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →